Welcome to our dedicated page for Forian SEC filings (Ticker: FORA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Forian Inc. SEC filings document the company's healthcare data analytics business, financial reporting, governance actions and capital-structure matters. Its Form 8-K disclosures include operating and financial results, material-event reports, accounting-firm changes, board changes, and exhibits furnished with earnings releases.
The filing record also covers corporate governance and shareholder-rights matters, including proxy materials for a statutory redomiciliation and the completed change of domicile from Delaware to Maryland. Related disclosures describe charter and bylaw changes, stockholder voting mechanics, material agreements, internal-control topics, and other formal records affecting Forian's public-company structure.
Forian Inc. General Counsel Caroline Strickland McGrail reported a disposition of 150,000 shares of common stock, reflecting unvested restricted stock units (RSUs) canceled in connection with the company’s merger. These RSUs were converted into a cash right based on a price of $2.17 per share at the merger’s effective time, leaving her with 0 shares directly owned after the transaction.
Forian Inc. notifies that its Common Stock is being removed from listing and registration on the Nasdaq Stock Market LLC via Form 25.
The Exchange states it has complied with 17 CFR 240.12d2-2 procedures and the issuer complied with Nasdaq rules governing voluntary withdrawal.
2025 Acquisition Company, LLC and its wholly owned subsidiary Bravo Merger Sub completed a cash tender offer and effected a merger to take Forian Inc. private. The Offer, which paid $2.17 per share, expired at one minute past 11:59 p.m. Eastern on May 14, 2026.
As of the Expiration Date, 6,444,415 shares were validly tendered and not withdrawn, which together with Parent beneficial ownership represented approximately 91% of the aggregate voting power. On May 15, 2026, Merger Sub accepted the tendered shares, completed the Merger under Maryland law, and Forian became a wholly owned subsidiary of Parent; Forian’s Nasdaq listing will be removed and its shares deregistered.
Forian Inc. amended its Schedule 14D-9 to report the results of the tender offer and completion of the merger. The offer purchased outstanding shares at $2.17 per share. The offer expired at 11:59 p.m. ET on May 14, 2026 with 6,444,415 shares validly tendered, representing approximately 91% of aggregate voting power as of the expiration. On May 15, 2026, Purchaser accepted for payment all validly tendered shares, effected the merger under Section 3-106.1 of the MGCL, and Forian became a wholly owned subsidiary of Parent. Shares are expected to cease trading and be delisted from Nasdaq prior to the opening of business on May 18, 2026, and Parent intends to terminate the Shares' registration and suspend reporting under the Exchange Act.
Forian Inc. has completed its acquisition by 2025 Acquisition Company, LLC through a cash tender offer and merger. Stockholders who tendered or held Forian common stock immediately before the merger will receive $2.17 per share in cash, without interest and subject to tax withholding.
The tender offer expired on May 14, 2026, with 6,444,415 shares validly tendered and not withdrawn, which, together with shares already owned by the buyer, satisfied the minimum condition. On May 15, 2026, the merger closed, Forian became a wholly owned subsidiary of Parent, and all in‑the‑money options, RSUs and restricted stock were cashed out based on the same $2.17 price, subject to vesting terms.
Forian’s common stock will be delisted from Nasdaq, and the company plans to terminate SEC registration and suspend periodic reporting, making Forian a privately held company. The existing board members resigned at closing, leaving Max Wygod as sole director, and the articles of incorporation and bylaws were amended and restated for the surviving corporation.
Forian Inc. reported Q1 2026 revenue of $6.9 million, down slightly from $7.1 million a year earlier, while net loss widened to $3.4 million from $1.1 million as costs rose sharply. Gross margin fell to 29% from 56%, driven mainly by higher information licensing and processing expenses.
Adjusted EBITDA deteriorated to a loss of $2.3 million from essentially breakeven, reflecting increased research and development spending, higher sales and marketing, and $0.6 million of strategic review and transaction costs. Cash and cash equivalents increased to $31.0 million, helped by liquidating marketable securities and fully repaying prior convertible notes.
After quarter-end, Forian signed a merger agreement under which a buyer group plans a cash tender offer at $2.17 per share, followed by a merger that would make Forian a wholly owned subsidiary. The company also faces stockholder demand letters challenging disclosures and board actions related to these transactions.
Bravo Merger Sub, Inc. and 2025 Acquisition Company, LLC filed Amendment No. 2 to the Schedule TO for their cash tender offer to acquire all outstanding shares of Forian Inc. at $2.17 per share. The amendment adds written fairness positions from Max Wygod and Adam Dublin, each explaining their roles, equity interests in Parent, and stating they believe the Offer and proposed merger are substantively and procedurally fair to Forian's unaffiliated security holders. Both executives note they did not obtain independent fairness analyses and that their statements are made to comply with Rule 13e-3 disclosures. Other terms of the Offer remain incorporated by reference.
Forian Inc. filed Amendment No. 1 to its Schedule 14D-9 to supplement its recommendation regarding the cash tender offer by 2025 Acquisition Company, LLC and Bravo Merger Sub, Inc. to acquire all outstanding common shares at $2.17 per share. The amendment adds director and officer background (Schedule I), describes agreements among certain stockholder consortium members and Parent (including a Contribution Agreement resulting in Parent owning 21,991,929 Shares, or 70.39% of issued and outstanding shares), and discloses an Equity Commitment Letter in which a Sponsor committed up to $5,500,000 to fund the Offer and Merger. The filing also states certain current executives (including Max Wygod, Michael Vesey, and Caroline McGrail) are understood to have roles with the Surviving Corporation and summarizes selected valuation analyses performed by Houlihan Lokey.
Forian Inc. is subject to a cash tender offer by 2025 Acquisition Company, LLC and its wholly owned subsidiary Bravo Merger Sub, Inc. to acquire the remaining public common shares for $2.17 per share, payable net in cash on the terms in the Offer to Purchase and Letter of Transmittal.
The filing amends the Schedule TO to add consolidated historical financials for Forian: $30.26M revenue and a $2.87M net loss for year ended December 31, 2025; $12.9M cash and $18.65M marketable securities at year-end. The Buyer Parties beneficially own approximately 70.61% of Forian; completion would increase their ownership to 100% and make Forian an indirect wholly owned subsidiary.
Forian Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III disclosures on directors, executive officers, compensation, ownership and auditor matters, plus updated officer certifications.
The company reported an aggregate market value of common stock held by non‑affiliates of about $34 million as of June 30, 2025 and 31,240,882 common shares outstanding as of April 27, 2026. Governance disclosures show a mostly independent board with specialized healthcare, technology and finance backgrounds, and outline its code of ethics and insider trading policy.
Compensation tables show 2025 total pay of $461,000 for CEO Max Wygod, $965,672 for Chief Strategy Officer Adam Dublin and $933,066 for CFO Michael Vesey, including equity awards and, for the CFO, a performance bonus. Ownership data highlight that 2025 Acquisition Company, LLC and related insiders beneficially own over 70% of the common stock, indicating highly concentrated control.